Login to Your Account



Summit's phase II peak scaled in C. difficile bid; phase III effort to come

By Randy Osborne
Staff Writer

Monday, November 23, 2015

Phase II results with oral ridinilazole against the potentially lethal Clostridium difficile bug "exceeded our wildest expectations" said Glyn Edwards, CEO of Oxford, U.K.-based Summit Therapeutics plc, which is working on the phase III program's design as partnership talks continue.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription